SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

NCT02766140 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped difficulty in recruitment

Conditions

Non Squamous Non Small Cell Lung

Interventions

DRUG: SHR1020 plus Docetaxel
DRUG: Placebo plus Docetaxel

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Collaborators

[object Object]